SURVIVAL DETERMINANTS IN PATIENTS WITH ADVANCED OVARIAN-CANCER

被引:24
作者
ANSELL, SM [1 ]
RAPOPORT, BL [1 ]
FALKSON, G [1 ]
RAATS, JI [1 ]
MOEKEN, CM [1 ]
机构
[1] UNIV PRETORIA,DEPT MED ONCOL,POB 667,PRETORIA,SOUTH AFRICA
关键词
D O I
10.1006/gyno.1993.1195
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
An analysis was performed on 127 consecutive women with advanced measurable ovarian cancer to evaluate factors predicting for survival. All patients received cis-platinum-based chemotherapy as treatment for stage IIIB to stage IV disease. Eighteen clinical, radiological, and biochemical parameters were subjected to univariate and multivariate analyses. Recursive partitioning and amalgamation (RPA) was used to define prognostic subsets with different survival potentials. In the univariate analysis, factors that predicted for survival were weight loss, histology, stage, number of metastases, presence of ascites, size of the residual tumor, and rate of tumor response. When these significant variables were included in a Cox model, advanced stage of disease, histology other than adenoserous carcinoma, the presence of tumor bulk, and a slow rate of tumor response independently predicted a poorer survival. Using the three disease-related prognostic variables, a RPA model was derived and three groups were identified with median survival times of 76, 28, and 21 months, respectively (P = 0.001). The best survival time of 76 months was seen in patients with stage III, non-bulky, adenoserous ovarian carcinoma. It is concluded that the rate of tumor response is important in predicting the outcome of patients with ovarian cancer. Furthermore, the interactions between prognostic factors are emphasized by the RPA model and a subgroup of patients with a projected 10-year survival of 50% is identified. © 1993 Academic Press, Inc.
引用
收藏
页码:215 / 220
页数:6
相关论文
共 19 条
[1]   SURVIVAL DETERMINANTS IN EXTENSIVE-STAGE NON-SMALL-CELL LUNG-CANCER - THE SOUTHWEST-ONCOLOGY-GROUP EXPERIENCE [J].
ALBAIN, KS ;
CROWLEY, JJ ;
LEBLANC, M ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (09) :1618-1626
[2]  
Byar DP, 1984, CANCER CLIN TRIALS, P423
[3]  
Ciampi A., 1988, Statistical Software Newsletter, V14, P78
[4]  
COX DR, 1972, J R STAT SOC B, V34, P187
[5]   CHOICE OF POSTOPERATIVE THERAPY BASED ON PROGNOSTIC FACTORS [J].
DEMBO, AJ ;
BUSH, RS .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1982, 8 (05) :893-897
[6]   THE IMPORTANCE OF DOSE INTENSITY IN CHEMOTHERAPY OF METASTATIC BREAST-CANCER [J].
HRYNIUK, W ;
BUSH, H .
JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (11) :1281-1288
[7]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[8]  
LEVIS A, 1987, CANCER, V60, P1713, DOI 10.1002/1097-0142(19871015)60:8<1713::AID-CNCR2820600804>3.0.CO
[9]  
2-C
[10]   PROGNOSTIC FACTORS IN ADVANCED EPITHELIAL OVARIAN-CANCER [J].
MARSONI, S ;
TORRI, V ;
VALSECCHI, MG ;
BELLONI, C ;
BIANCHI, U ;
BOLIS, G ;
BONAZZI, C ;
COLOMBO, N ;
EPIS, A ;
FAVALLI, G ;
GAMBINO, A ;
LANDONI, F ;
MAGGI, R ;
PECORELLI, S ;
PRESTI, S ;
VASSENA, L ;
ZANABONI, F ;
MANGIONI, C .
BRITISH JOURNAL OF CANCER, 1990, 62 (03) :444-450